Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.40.
CRDL has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Monday. Rodman & Renshaw assumed coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price for the company. Finally, RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th.
Read Our Latest Analysis on Cardiol Therapeutics
Institutional Inflows and Outflows
Cardiol Therapeutics Trading Down 2.5 %
CRDL opened at $1.17 on Friday. The firm has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $1.68. Cardiol Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $3.12. The company has a market cap of $96.65 million, a price-to-earnings ratio of -3.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
- Five stocks we like better than Cardiol Therapeutics
- Manufacturing Stocks Investing
- Finding Hidden Gems: Unconventional Penny Stock Investing
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Price Targets on NVIDIA Rise in Front of Earnings
- Stock Splits, Do They Really Impact Investors?
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.